

AQUASOL A PARENTERAL- water-miscible retinyl palmitate injection, solution **Rising Pharma Holdings, Inc.**


AQUASOL A® Parenteral

Water-Miscible Retinyl Palmitate
50,000 USP units/mL (15 mg retinol)
For Intramuscular Use.

Rx only

DESCRIPTION

AQUASOL A® Parenteral (Water-Miscible Retinyl Palmitate) provides 50,000 USP Units of vitamin A per mL as retinol (C₂₀H₃₀O) in the form of retinyl palmitate, a light yellow to amber oil. Contains 0.5% chlorobutanol as preservative; 12% polysorbate 80, 0.1% citric acid, and sodium hydroxide to adjust pH. The structural formula of retinol is:



Ordinarily oil-soluble, the retinyl palmitate in this product has been water solubilized by special processing* and is available in a water solution for intramuscular injection.

One USP Unit is equivalent to one international unit (IU) and to 0.3 mcg of retinol or 0.6 mcg of beta-carotene.

*Oil-soluble retinyl palmitate water solubilized with polysorbate 80.

CLINICAL PHARMACOLOGY

Beta-carotene, retinol, and retinal have effective and reliable vitamin A activity. Retinal and retinol are in chemical equilibrium in the body and have equivalent antioxidant activity. Retinal combines with the rod pigment, opsin, in the retina to form rhodopsin, necessary for visual dark adaptation. Vitamin A prevents retardation of growth and preserves the epithelial cells' integrity. Normal adult liver storage is sufficient to satisfy two years' requirements of vitamin A.

Vitamin A is readily absorbed from the gastrointestinal tract, where the biosynthesis of vitamin A from beta-carotene takes place. Vitamin A absorption requires bile salts, pancreatic lipase, and dietary fat. It is transported in the blood to the liver by the chylomicron fraction of the lymph. Vitamin A is stored in Kupffer cells of the liver mainly as the palmitate. Normal serum vitamin A is 80-300 Units per 100 mL (plasma range is 30-70 mcg per dl) and for carotenoids 270-753 Units per 100 mL. The normal adult liver contains approximately 100 to 300 micrograms per gram, mostly as retinol palmitate.

INDICATIONS

Retinyl palmitate injection is effective for the treatment of vitamin A deficiency.

The parenteral administration is indicated when the oral administration is not feasible as in anorexia, nausea, vomiting, pre- and postoperative conditions, or it is not available as in the "Malabsorption Syndrome" with accompanying steatorrhea.

Pediatric Use: Vitamin A treatment for deficiency states has been recognized as an especially effective and important therapy in the pediatric population.

Vitamin A supplementation for deficiency states in this population has been addressed by the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition, by the American Society for Parenteral and Enteral Nutrition, and by the World Health Organization.

CONTRAINDICATIONS

The intravenous administration. Hypervitaminosis A. Sensitivity to any of the ingredients in this preparation.

Use in Pregnancy: Safety of amounts exceeding 6,000 Units of vitamin A daily during pregnancy has not been established at this time. The use of vitamin A in excess of the recommended dietary allowance may cause fetal harm when administered to a pregnant woman. Animal reproduction studies have shown fetal abnormalities associated with overdosage in several species. Malformations of the central nervous system, the eye, the palate, and the urogenital tract are recorded. Vitamin A in excess of the recommended dietary allowance is contraindicated in women who are or may become pregnant. If vitamin A is used during pregnancy, or if the patient becomes pregnant while taking vitamin A, the patient should be apprised of the potential hazard to the fetus.

WARNINGS

Avoid overdosage. Keep out of the reach of children.

Pediatric Use: Polysorbates have been associated with E-Ferol syndrome (thrombocytopenia, renal dysfunction, hepatomegaly, cholestasis, ascites, hypotension and metabolic acidosis) in low birthweight infants.

PRECAUTIONS

General: Protect from light. Prolonged daily dose administration over 25,000 Units vitamin A should be under close supervision. Blood level assays are not a direct measure of liver storage. Liver storage should be adequate before discontinuing therapy. Single vitamin A deficiency is rare. Multiple vitamin deficiency is expected in any dietary deficiency.

Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.

Carcinogenesis: There are no studies that show that administration of vitamin A will

cause or prevent cancer.

Pregnancy:

See **CONTRAINDICATIONS** section.

Nursing Mothers: The U.S. Recommended Daily Allowance (RDA) of vitamin A (5,000 Units) is recommended for nursing mothers.

ADVERSE REACTIONS

See **OVERDOSAGE** section. Anaphylactic shock and death have been reported using the intravenous route. Allergic reactions have been reported rarely with administration of **AQUASOL A® Parenteral** including one case of an anaphylactoid type reaction.

To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

The following amounts have been found to be toxic orally. Toxicity manifestations depend on the age, dosage, size, and duration of administration.

Acute toxicity — single dose (25,000 Units/kg body weight)

Infant: 350,000 Units

Adult: Over 2 million Units

Chronic toxicity (4,000 Units/kg body weight for 6 to 15 months)

Infants 3 to 6 months old: 18,500 Units (water dispersed)/day for 1 to 3 months.

Adult: 1 million Units daily for three days; 50,000 Units daily for longer than 18 months; 500,000 Units daily for two months.

Hypervitaminosis A Syndrome:

1. *General manifestations:*

Fatigue, malaise, lethargy, abdominal discomfort, anorexia, and vomiting.

2. *Specific manifestations:*

a. Skeletal: hepatotoxicity, hard tender cortical thickening over the radius and tibia, migratory arthralgia, slow growth, and premature closure of the epiphysis leading to arrested bone growth in children.

b. Central Nervous System: irritability, headache, and increased intracranial pressure as manifested by bulging fontanels, papilledema, and exophthalmos.

c. Dermatologic: fissures of the lips, drying and cracking of the skin, alopecia, scaling, massive desquamation, and increased pigmentation.

d. Systemic: hypomenorrhea, hepatosplenomegaly, hepatotoxicity, jaundice, leukopenia, retinyl palmitate plasma level over 1,200 Units/100 mL.

The treatment of hypervitaminosis A consists of immediate withdrawal of the vitamin along with symptomatic and supportive treatment.

DOSAGE AND ADMINISTRATION

For intramuscular use.

I. Adults

100,000 Units daily for three days followed by 50,000 Units daily for two weeks.

II. Pediatric patients 1 to 8 years old

17,500 to 35,000 Units daily for 10 days.

III. Infants

7,500 to 15,000 Units daily for 10 days.

Follow-up therapy with an oral therapeutic multivitamin preparation, containing 10,000 to 20,000 Units vitamin A for adults and for pediatric patients over 8 years old, and 5,000 to 10,000 Units for infants and other pediatric patients under 8 years old, is recommended daily for two months. Low birth-weight infants may require additional retinyl palmitate though the exact dosing in these pediatric patients has not been established. In malabsorption, the parenteral route must be used for an equivalent preparation.

Poor dietary habits should be corrected and an abundant and well-balanced dietary intake should be prescribed.

HOW SUPPLIED

AQUASOL A® Parenteral (Water-Miscible Retinyl Palmitate) is available as:

Unit of Sale	Concentration	Each
NDC 64980-721-02 Carton of 1	50,000 USP units/mL (15 mg retinol/mL)	NDC 64980-721-02 2 mL Single-Dose Vial

Store at 2° to 8°C (36° to 46°F). Do not freeze.

Distributed by:

Rising Pharma Holdings, Inc.
East Brunswick, NJ 08816

Made in India

Code No.: TN/DRUGS/616/1996

Issued: 01/2026

PIA72102-00

PLF295

US/LF/171 V01

PRINCIPAL DISPLAY PANEL - 2 mL Vial Label

2 mL Single-Dose Vial

Rx only

NDC 64980-721-02

AQUASOL A®

Parenteral

Water-Miscible Retinyl Palmitate

50,000 USP units/mL (15 mg retinol)

For Intramuscular Use.

Sterile

Rising NDC 64980-721-02
AQUASOL A[®]
Parenteral
Water-Miscible Retinyl
Palmitate
50,000 USP units/mL
(15 mg retinol)
For Intramuscular Use.
2 mL Single-Dose Vial **Rx only**

Sterile
Store at 2° to 8°C (36° to 46°F).
Do not freeze.
Contains: 0.5% chlorobutanol,
12% polysorbate 80, 0.1% citric
acid, NaOH to adjust pH and WFI.

10100364980721028

Distributed by:
Rising Pharma Holdings, Inc.
East Brunswick, NJ 08816
Made in India
Code No.: TN/DRUGS/616/1996
Issued: 01/2026
LA72102-00 PLC694

LOT: *
EXP.

US/323/LB/228 V01

PRINCIPAL DISPLAY PANEL - Carton Label

2 mL

Single-Dose Vials

NDC 64980-721-02

Rx only

AQUASOL A[®]

Parenteral


Water-Miscible Retinyl Palmitate

50,000 USP units/mL

(15 mg retinol)

For Intramuscular Use.

Sterile



AQUASOL A PARENTERAL

water-miscible retinyl palmitate injection, solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:64980-721
Route of Administration	INTRAMUSCULAR		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
VITAMIN A PALMITATE (UNII: 1D1K0N0VVC) (RETINOL - UNII:G2SH0XKK91)	RETINOL	15 mg in 1 mL

Inactive Ingredients

Ingredient Name	Strength
CHLOROBUTANOL (UNII: HM4YQM8WRC)	
POLYSORBATE 80 (UNII: 6OZP39ZG8H)	
CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:64980-721-02	1 in 1 CARTON	02/27/2026	
1		2 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA006823	02/27/2026	

Labeler - Rising Pharma Holdings, Inc. (116880195)

Establishment

Name	Address	ID/FEI	Business Operations
Maiva Pharma Private Limited		725656438	analysis(64980-721) , label(64980-721) , manufacture(64980-721) , pack(64980-721)

Revised: 3/2026

Rising Pharma Holdings, Inc.